This newest addition to the PliaFX family of bone void fillers, which includes PliaFX Prime and PliaFX Strip, will be commercialised through Johnson & Johnson MedTech from August 2024. Credit: Shutterstock / SORASIT SRIKHAM-ON.

Regenerative health company LifeNet Health has announced the launch of its newest bone allograft designed in collaboration with healthcare giant Johnson & Johnson MedTech as the company plans to make its entrance into the demineralised bone matrix (DBM) market.

Lifenet says that its bone allograft, dubbed PliaFX Pak, combines mineralised bone chips with precision-machined moldable demineralised fibres designed to give surgeons a means of addressing voids and defects in orthopaedic spine and trauma procedures.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Market research carried out by GlobalData found that the US bone grafts and substitutes market will generate $2.2bn in 2030 in the US, increasing at a compound annual growth rate (CAGR) of 3.2% from $1.6bn in 2020.

This newest addition to the PliaFX family of bone void fillers, which includes PliaFX Prime and PliaFX Strip, will be commercialised through Johnson & Johnson MedTech this month.

The company insists that its PliaFX Pak stands out due to its ease of handling with interlocking fibres within the mouldable graft that can be transferred quickly and easily to the surgical site, eliminating the need for the previously used one-by-one transfer associated with traditional bone.

See Also:

The osteoconductive scaffold that forms within the gel has a large surface area and is an interconnected network of bone fibres and chips, supports cell attachment and is designed to promote bone and blood vessel formation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Rich Rice, vice president of orthopedics at LifeNet Health said “LifeNet Health’s advanced fibre technology in PliaFX Pak sets a new standard for bone graft handling and performance. This innovation provides surgeons with a superior option that not only meets clinical needs but also enhances surgical efficiency.”

The PliaFX line of products joins some of the company’s other offerings, including its decellularised placental membrane for wound healing, Matrion.

Elsewhere in the field of bone graft technology Massachusetts-based orthobiologic and spine-fusion firm, Bone Biologics Corporation, has announced that it has treated the first two patients in a pilot clinical study of its NB1 bone graft device. At the same time, UK-based medical device company Biocomposites has announced the initiation of two Phase II clinical trials of its pharmaceutical-grade calcium sulphate biodegradable bone graft, STIMULAN.